Cancer pain cancer pain nefopam efficacy
Conditions
Interventions
The intervention group will receive nefopam 20 mg in 0.9% normal saline 100 ml drip intravenously every 8 hours for 3 times. They will be offerred morphine to rescue the breakthrough pain via intrave
Experimental Drug,Placebo Comparator No treatment
Sponsors
Ramathibodi hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-80 years 2. Patients who has moderate to severe cancer pain (numeric rating scale 4/10-10/10) who needs analgesics to control pain 3. Patients who is willing to enroll the study
Exclusion criteria
Exclusion criteria: 1. Patients who cannot evaluate their pain into numeric rating scale 2. Patients who are not able to use IV-PCA machine 3. Patients who are allergic to intravenous morphine 4. Patients who are on chemotherapy or radiation therapy during study period 5. Patients who undergo an operation within one week 6. Patients with a history of convulsive disorder 7. Patients who are diagnosed ischemic heart disease 8. Patients who are taking MAOI within 30 days before study period 9. Pregnants or breast feeing patients 10. Patients who deny to enroll the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analgesic efficacy record data every 4 hours until completing 48 hours numeric rating scale and dose of opioids used | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of side effects from nefopam during 48 hours after starting intervention record incidence of side effects | — |
Countries
Thailand
Contacts
Public ContactKoravee Pasutharnchat
Ramathibodi hospital
Outcome results
None listed